HY-50 Vet 17 mg/ml Solution for Injection

מדינה: הממלכה המאוחדת

שפה: אנגלית

מקור: VMD (Veterinary Medicines Directorate)

מרכיב פעיל:

Sodium Hyaluronate

זמין מ:

Dechra Limited

קוד ATC:

QM09AX01

INN (שם בינלאומי):

Sodium Hyaluronate

טופס פרצבטיות:

Solution for injection

סוג מרשם:

POM-V - Prescription Only Medicine – Veterinarian

קבוצה תרפויטית:

Horses

איזור תרפויטי:

Anti Inflammatory

מצב אישור:

Authorized

תאריך אישור:

1998-06-12

מאפייני מוצר

Revised: March 2016
AN: 01470/2015
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
HY-50 Vet 17 mg/ml solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Sodium Hyaluronate
17 mg/ml
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection
Clear, colourless, viscous solution
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horse.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For intra-articular and intravenous treatment of lameness caused by
joint
dysfunction associated with non-infectious synovitis.
4.3
CONTRAINDICATIONS
Do not use in cases of joint infection.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Radiographic evaluation should be carried out in cases of acute,
severe lameness to ensure that the joints are free from serious
fractures.
Revised: March 2016
AN: 01470/2015
Page 2 of 5
ii.
Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Not applicable.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Transient mild swelling and/or heat has been reported in treated
joints
(2,7%). These self-limiting local signs resolve spontaneously within
48
hours, and do not negate a successful therapeutic outcome.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Safety in pregnant and lactating mares has not been documented. Use
only according to the benefit/risk assessment by the responsible
veterinarian.
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
No data available.
4.9
AMOUNTS TO BE ADMINISTERED AND ADMINISTRATION ROUTE
Intravenous use: 3 ml intravenously repeated at weekly intervals for a
total of three treatments.
For single intra-articular injection: 3 ml (51 mg) intra-articularly
into
medium sized and large joints. Smaller joints such as intertarsal,
tarsometatarsal and interphalangeal joints can be treated with a 1.5
ml
dose (25.5